5/17/2013

Nordion has inked a deal with Navidea Biopharmaceuticals, agreeing to manufacture the imaging agent NAV5001 for Navidea's Phase IIb and Phase III trials expected to start this year. The agent is used in diagnosing Parkinsonian syndromes and dementia with Lewy bodies. The deal is initially effective for three years.

Related Summaries